The physician's role in selecting a factor replacement therapy

Haemophilia

Volumn 12, Issue SUPPL. 1, 2006, Pages 21-25

  Pipe, Steven W ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Haemophilia; Pathogens; Plasma; Recombinant; Therapy

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8;

BLOOD TRANSFUSION; COST BENEFIT ANALYSIS; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; GOVERNMENT; HEALTH CARE ORGANIZATION; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERPERSONAL COMMUNICATION; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; PARVOVIRUS; PARVOVIRUS INFECTION; PATIENT ADVOCACY; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRION; PRIORITY JOURNAL; REIMBURSEMENT; RELIABILITY; REVIEW; RISK ASSESSMENT; SAFETY; SCREENING TEST; UNITED STATES; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

BLOOD COMPONENT TRANSFUSION; COMMUNICABLE DISEASES, EMERGING; DISEASE TRANSMISSION, HORIZONTAL; GUIDELINE ADHERENCE; HEMOPHILIA A; HUMANS; PATIENT SELECTION; PHYSICIAN'S ROLE; UNITED STATES;

EID: 33646016307     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01197.x     Document Type: Review

References (24)

1. Committee to Study HIV Transmission Through Blood and Blood Products, Institute of Medicine. Leveton LB, Sox HC Jr, Stoto MA, eds. HIV and the Blood Supply: An Analysis for Crisis Decisionmaking. Washington, DC: National Academy Press, 1995; 1-17.
2. Stoto MA. The precautionary principle and emerging biological risks: lessons from swine flu and HIV in blood products. Public Health Rep 2002; 117: 546-52.
3. National Hemophilia Foundation. MASAC recommendations Concerning the Treatment of Hemophilia and Other Bleeding Disorders. MASAC Document no. 151, November 2003. Published online at http://www.hemophilia.org/ research/masac/masac151.pdf. Accessed July 2004.
4. Chandra S, Groener A, Feldman F. Effectiveness of alternative treatments for reducing potential viral contaminants from plasma-derived products. Thromb Res 2002; 105: 391-400.
5. Hoots WK. History of plasma-product safety. Transfus Med Rev 2001; 15 (Suppl. 1): 3-10.
6. Fischer G, Hoots WK, Abrams C. Viral reduction techniques: Types and purpose. Transfus Med Rev 2001; 15 (2 Suppl. 1): 27-39.
7. Centers for Disease Control and Prevention. CDC's Universal Data Collection project: Blood safety. February 2002. Published online at http://www.cdc.gov/ncbddd/hbd/blood_safety_facts.htm. Accessed March 2005.
8. Centers for Disease Control and Prevention, National Center for Infectious Diseases. 2005 West Nile virus viremic blood donor activity in the United States. Reported to the CDC as of November 15, 2005. Available at http://www.cdc.gov/ncidod/dvbid/westnile/ surv&control05Maps_Viremic.htm. Accessed November 2005.
9. Miekka SI, Busby TF, Reid B, Pollock R, Ralston A, Drohan WN. New methods for inactivation of lipid-enveloped and non-enveloped viruses. Haemophilia 1998; 4: 402-8.
10. Yokoyama T, Murai K, Murozuka T, Wakisaka A, Tanifuji M, Fujii N et al. Removal of small non-enveloped viruses by nanofiltration. Vox Sang 2004; 86: 225-9.
11. Santagostino E, Mannucci PM, Gringeri A et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion 1997; 37: 517-22.
12. Soucie JM, Siwak EB, Hooper WC, Evatt BL, Hollinger FB and the Universal Data Collection Project Working Group. Human parvovirus B19 in young male patients with hemophilia A: Associations with treatment product exposure and joint range-of-motion limitation. Transfusion 2004; 44: 1179-85.
13. Brown SA. Issues in making a therapeutic choice: Recombinant and/or human-derived products. Haemophilia 2000; 6: 12-9.
14. Aledort LM. Making a therapeutic choice: Human versus recombinant fractions -can we do it ? Haemophilia 2001; 7 (Suppl. 1): 1-3.
15. Soucie JM, Richardson LC, Evatt BL et al. Risk factors for infection with HBV and HCV in a large cohort of hemophiliac males. Transfusion 2001; 41: 338-43.
16. Chambost H, Ljung R. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia 2005; 11: 92-9.
17. Giangrande P., Haemophilia B. Christmas disease. Expert Opin Pharmacother 2005; 6: 1517-24.
18. Giles AR, Rivard GE, Teitel J, Walker I. Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy. Transfus Sci 1998; 19: 139-48.
19. Association of Hemophilia Clinic Directors of Canada. Clinical practice guidelines: Hemophilia and von Willebrand's disease: 2. Management (Edition 2, Update 2). July 7, 1999. Published online at http://www.ahcdc.ca/vWDManagement.html. Accessed April 2005.
20. United Kingdom Haemophilia Centre Doctors' Organisation on behalf of The Department of Health Forward Planning and Monitoring Group. Rollout of Recombinant Products for all Adult Haemophilia Patients in England: Report of 2003/2004. September 2004. Published online at http://www.dh.gov.uk/assetRoot/04/09/00/63/04090063.pdf. Accessed September 2005.
21. Farrugia A. Evolving perspectives in product safety for haemophilia. Haemophilia 2002; 8: 236-43.
22. Mauser-Bunschoten EP, Roosendaal G, van den Berg HM. Product choice and haemophilia treatment in the Netherlands. Haemophilia 2001; 7: 8.
23. Mantovani LG, Monzini MS, Mannucci PM, Scalone L, Villa M, Gringeri A. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: A discrete choice experiment. Haemophilia 2005; 11: 589-97.
24. Miller R. The responsibility of separating truth from myth to patient and family. Haemophilia 2001; 7: 91-5.